Transdermal delivery system containing galantamine or salts thereof

Abstract

The present invention provides a transdermal delivery system, which comprises a drug-containing matrix layer comprising: galantamine or its pharmaceutically acceptable salt as an active ingredient; and a styrene-butadiene-styrene copolymer or a styrene-isoprene-styrene copolymer as an adhesive.

1 . A transdermal delivery system, which comprises a drug-containing matrix layer comprising: galantamine or its pharmaceutically acceptable salt as an active ingredient; and a styrene-butadiene-styrene copolymer or a styrene-isoprene-styrene copolymer as an adhesive. 
     
     
         2 . The transdermal delivery system of  claim 1 , wherein the transdermal delivery system consists of a backing layer, the drug-containing matrix layer, and a release layer. 
     
     
         3 . The transdermal delivery system of  claim 1 , wherein the galantamine or its pharmaceutically acceptable salt is present in an amount ranging from 0.5 to 20% by weight, based on the total weight of the drug-containing matrix layer. 
     
     
         4 . The transdermal delivery system of  claim 1 , wherein the galantamine or its pharmaceutically acceptable salt is present in an amount ranging from 10 to 20% by weight, based on the total weight of the drug-containing matrix layer. 
     
     
         5 . The transdermal delivery system of  claim 1 , wherein the adhesive is present in an amount ranging from 70 to 95% by weight, based on the total weight of the drug-containing matrix layer. 
     
     
         6 . The transdermal delivery system of  claim 1 , further comprising one or more permeation enhancers selected from the group consisting of propylene glycol laurate, lauryl alcohol, triacetin, isopropyl myristate, cineole, polyoxyethylene lauryl ether, oleoyl macrogol glyceride, and caprylocaproyl macrogol glyceride. 
     
     
         7 . The transdermal delivery system of  claim 6 , wherein the permeation enhancer is polyoxyethylene lauryl ether. 
     
     
         8 . The transdermal delivery system of  claim 6 , wherein the permeation enhancer is present in an amount ranging from 0.5 to 10% by weight, based on the total weight of the drug-containing matrix layer. 
     
     
         9 . The transdermal delivery system of  claim 6 , wherein the permeation enhancer is present in an amount of 5% by weight, based on the total weight of the drug-containing matrix layer. 
     
     
         10 . The transdermal delivery system of  claim 1 , wherein the drug-containing matrix layer has a thickness ranging from 50 μm to 100 μm. 
     
     
         11 . The transdermal delivery system of  claim 1 , wherein the drug-containing matrix layer has a thickness ranging from 50 μm to 80 μm.